Can Combination Influenza and COVID-19 Vaccines Close the Coverage Gap in Germany? A Multi-Source Surveillance and Scenario Analysis
Vaccines · 14.11.2026 · 14 (11) · 982
DOI: 10.3390/vaccines14110982 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 14.11.2026. Verfasst von Stefan M. Scholz und 3 weiteren Autor:innen. Die Arbeit nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Moderna, Inc..
Abstract (Originalsprache)
Background/Objectives: Influenza and COVID-19 cause substantial seasonal respiratory disease in Germany, albeit with varying intensity. We characterized the temporal relationship between disease burden and vaccination timing and explored potential changes in vaccination coverage of an influenza/COVID-19 combination vaccine using stated preferences.
Methods
We retrospectively analyzed German surveillance, hospital, electronic medical record (EMR), and vaccine-preference data. EMR data from approximately 2000 outpatient practices described vaccination among adults aged ≥ 60 years in 2023/24 and 2024/25. Stated preferences were combined with baseline, observed vaccination states in a scenario analysis.
Results
During the 2023/24 and 2024/25 seasons, COVID-19 burden was concentrated mainly from October to December, followed by influenza burden from December through March, peaking in January–February. Vaccination against both diseases was concentrated in September–November. EMR-estimated influenza vaccination coverage was approximately 47% and 45%, whereas COVID-19 coverage declined from approximately 29% to 20%. Same-day administration of both vaccines occurred in 10.1% and 9.5% of adults aged ≥ 60 years, respectively. In the preference survey, 56.7% of those aged ≥ 50 years selected the combination vaccine. A scenario applying stated survey preferences to EMR baseline vaccination states and holding the unvaccinated share fixed, resulted in model-projected increases of 3.2 and 15.2 percentage points in influenza and COVID-19 coverage, respectively, for 2024/25.
Conclusions
The shared vaccination window for COVID-19 and influenza, together with observed same-day administration and meaningful burden from both diseases during the broader respiratory season, supports the feasibility of combination vaccination. A combination vaccine could simplify delivery and improve coverage, particularly for COVID-19, although projected effects require confirmation in real-world studies.
Förderung
- Moderna, Inc.
Zitieren
APA
Scholz, S. M., Voigt, C., Weinke, T., & Pletz, M. W. (2026). Can Combination Influenza and COVID-19 Vaccines Close the Coverage Gap in Germany? A Multi-Source Surveillance and Scenario Analysis. Vaccines, 14(11), 982. https://doi.org/10.3390/vaccines14110982
Vancouver
Scholz SM, Voigt C, Weinke T, Pletz MW. Can Combination Influenza and COVID-19 Vaccines Close the Coverage Gap in Germany? A Multi-Source Surveillance and Scenario Analysis. Vaccines. 2026;14(11):982. doi:10.3390/vaccines14110982
BibTeX
@article{Scholz2026,
author = {Scholz, Stefan M. and Voigt, Cornelia and Weinke, Thomas and Pletz, Mathias W.},
title = {Can Combination Influenza and COVID-19 Vaccines Close the Coverage Gap in Germany? A Multi-Source Surveillance and Scenario Analysis},
journal = {Vaccines},
year = {2026},
volume = {14},
number = {11},
pages = {982},
doi = {10.3390/vaccines14110982}
}
EUVIMED